

IN THE CLAIMS

Kindly amend the claims as follows:

1. (currently amended): A crystalline polymorph Form G of (\pm)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt according to claim 3 which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å): 7.6 (vs), 6.10 (s), and 4.37 (s), wherein (vs) = very strong intensity and (s) = strong intensity.
2. (currently amended): A crystalline polymorph Form G of (\pm)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt according to claim 3[[1]] which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å): 10.1 (m), 7.6 (vs), 6.10 (s), 5.09(m), 4.37 (s) and 3.07(m), wherein (vs) = very strong intensity, (s) = strong intensity and (m) = medium intensity.
3. (currently amended): A crystalline polymorph Form G of (\pm)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt according to claim 1 which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å): 29.2 (w), 15.0 (vw), 10.1 (m), 7.6 (vs), 6.10 (s), 5.09(m), 4.37 (s), 3.83 (w) and 3.07(m), wherein (vs) = very strong intensity, (s) = strong intensity, (m) = medium intensity, (w) = weak intensity and (vw) = very weak intensity.
4. (currently amended): A process for the preparation of crystalline polymorph Form G according to claim 3[[1]], wherein Fluvastatin sodium is filtered off from an aqueous suspension.
5. (previously presented): A process according to claim 4 for in which the aqueous suspension is prepared from any of the known crystalline forms or the amorphous form of Fluvastatin sodium.
6. (original): A process according to claim 4 in which an aqueous suspension of Fluvastatin sodium is stirred before filtration.
7. (cancelled).

8. (currently amended): A process for the preparation of crystalline polymorph Form G according to claim 2, wherein Fluvastatin sodium is filtered off from an aqueous suspension.
9. (currently amended): A process for the preparation of crystalline polymorph Form G according to claim 1[3], wherein Fluvastatin sodium is filtered off from an aqueous suspension.